Andreia Rafaela Linhares Miranda

@iroca.eu

Experimental Pathology and Therapeutics Group
Portuguese Oncology Institute of Porto (IPO-Porto)

Andreia Rafaela Linhares Miranda


                  Download Compact PDF  
https://researchid.co/andreiamiranda
154

Scholar Citations

6

Scholar h-index

6

Scholar i10-index

RECENT SCHOLAR PUBLICATIONS

  • GlycoAvatars: bead-coated membrane models for studying the cancer-immune cells interactome
    A Miranda, M Relvas-Santos, C Lourenço, E Ferreira, DM Cunha, ...
    Communications Biology , 2026
    2026
  • CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape
    J Soares, D Ferreira, A Miranda, M Gonçalves, M Relvas-Santos, ...
    Cell Communication and Signaling , 2026
    2026
    Citations: 1
  • Cd44 glycoepitopes and chimeric vaccine glycoconjugates for cancer therapy and synthesis methods thereof
    JARDEC FERREIRA, AMN DA SILVA, RFN FREITAS, LJDEL SANTOS, ...
    US Patent App. 18/688,999 , 2025
    2025
  • E‐selectin affinity glycoproteomics reveals neuroendocrine proteins and the secretin receptor as a poor‐prognosis signature in colorectal cancer
    S Cotton, D Ferreira, M Relvas‐Santos, A Brandão, LP Afonso, A Miranda, ...
    Molecular Oncology 19 (3), 635-658 , 2025
    2025
    Citations: 5
  • Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells
    A Peixoto, D Ferreira, A Miranda, M Relvas-Santos, R Freitas, TS Veth, ...
    Iscience 28 (2) , 2025
    2025
    Citations: 10
  • Targeted and self-adjuvated nanoglycovaccine candidate for cancer immunotherapy
    R Freitas, E Ferreira, A Miranda, D Ferreira, M Relvas-Santos, F Castro, ...
    ACS nano 18 (14), 10088-10103 , 2024
    2024
    Citations: 20
  • A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy
    R Freitas, A Miranda, D Ferreira, M Relvas-Santos, F Castro, E Ferreira, ...
    Journal of Controlled Release 367, 540-556 , 2024
    2024
    Citations: 17
  • Immunomodulatory glycomedicine: Introducing next generation cancer glycovaccines
    R Freitas, A Peixoto, E Ferreira, A Miranda, LL Santos, JA Ferreira
    Biotechnology Advances 65, 108144 , 2023
    2023
    Citations: 28
  • A roadmap for translational cancer glycoimmunology at single cell resolution
    A Peixoto, A Miranda, LL Santos, JA Ferreira
    Journal of Experimental & Clinical Cancer Research 41 (1), 143 , 2022
    2022
    Citations: 16
  • Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion
    C Gaiteiro, J Soares, M Relvas-Santos, A Peixoto, D Ferreira, P Paulo, ...
    Theranostics 12 (7), 3150 , 2022
    2022
    Citations: 57
  • Glycoproteogenomics characterizes the CD44 splicing code driving bladder cancer invasion
    C Gaiteiro, J Soares, M Relvas-Santos, A Peixoto, D Ferreira, A Brandão, ...
    bioRxiv, 2021.09. 04.458979 , 2021
    2021

MOST CITED SCHOLAR PUBLICATIONS

  • Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion
    C Gaiteiro, J Soares, M Relvas-Santos, A Peixoto, D Ferreira, P Paulo, ...
    Theranostics 12 (7), 3150 , 2022
    2022
    Citations: 57
  • Immunomodulatory glycomedicine: Introducing next generation cancer glycovaccines
    R Freitas, A Peixoto, E Ferreira, A Miranda, LL Santos, JA Ferreira
    Biotechnology Advances 65, 108144 , 2023
    2023
    Citations: 28
  • Targeted and self-adjuvated nanoglycovaccine candidate for cancer immunotherapy
    R Freitas, E Ferreira, A Miranda, D Ferreira, M Relvas-Santos, F Castro, ...
    ACS nano 18 (14), 10088-10103 , 2024
    2024
    Citations: 20
  • A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy
    R Freitas, A Miranda, D Ferreira, M Relvas-Santos, F Castro, E Ferreira, ...
    Journal of Controlled Release 367, 540-556 , 2024
    2024
    Citations: 17
  • A roadmap for translational cancer glycoimmunology at single cell resolution
    A Peixoto, A Miranda, LL Santos, JA Ferreira
    Journal of Experimental & Clinical Cancer Research 41 (1), 143 , 2022
    2022
    Citations: 16
  • Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells
    A Peixoto, D Ferreira, A Miranda, M Relvas-Santos, R Freitas, TS Veth, ...
    Iscience 28 (2) , 2025
    2025
    Citations: 10
  • E‐selectin affinity glycoproteomics reveals neuroendocrine proteins and the secretin receptor as a poor‐prognosis signature in colorectal cancer
    S Cotton, D Ferreira, M Relvas‐Santos, A Brandão, LP Afonso, A Miranda, ...
    Molecular Oncology 19 (3), 635-658 , 2025
    2025
    Citations: 5
  • CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape
    J Soares, D Ferreira, A Miranda, M Gonçalves, M Relvas-Santos, ...
    Cell Communication and Signaling , 2026
    2026
    Citations: 1
  • GlycoAvatars: bead-coated membrane models for studying the cancer-immune cells interactome
    A Miranda, M Relvas-Santos, C Lourenço, E Ferreira, DM Cunha, ...
    Communications Biology , 2026
    2026
  • Cd44 glycoepitopes and chimeric vaccine glycoconjugates for cancer therapy and synthesis methods thereof
    JARDEC FERREIRA, AMN DA SILVA, RFN FREITAS, LJDEL SANTOS, ...
    US Patent App. 18/688,999 , 2025
    2025
  • Glycoproteogenomics characterizes the CD44 splicing code driving bladder cancer invasion
    C Gaiteiro, J Soares, M Relvas-Santos, A Peixoto, D Ferreira, A Brandão, ...
    bioRxiv, 2021.09. 04.458979 , 2021
    2021